• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BBLG

    Bone Biologics Corp

    Subscribe to $BBLG
    $BBLG
    Industrial Specialties
    Health Care

    Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

    IPO Year:

    Exchange: NASDAQ

    Website: bonebiologics.com

    Recent Analyst Ratings for Bone Biologics Corp

    DatePrice TargetRatingAnalyst
    See more ratings

    Bone Biologics Corp Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      11/14/24 7:19:34 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      11/13/24 11:14:34 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bone Biologics Corp

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      6/28/24 4:15:43 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Bone Biologics Corp

      SC 13G - Bone Biologics Corp (0001419554) (Subject)

      3/14/24 5:10:20 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Bone Biologics Corp (Amendment)

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      2/14/24 6:41:42 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Bone Biologics Corp (Amendment)

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      2/14/24 10:55:05 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Bone Biologics Corp (Amendment)

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      2/13/24 8:03:32 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Bone Biologics Corp (Amendment)

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      1/2/24 3:34:48 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Bone Biologics Corp (Amendment)

      SC 13G/A - Bone Biologics Corp (0001419554) (Subject)

      12/20/23 5:21:39 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Bone Biologics Corp

      SC 13G - Bone Biologics Corp (0001419554) (Subject)

      11/27/23 6:10:28 AM ET
      $BBLG
      Industrial Specialties
      Health Care

    Bone Biologics Corp Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Frelick Jeff

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/21/25 6:10:12 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Walsh Deina H

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/21/25 6:06:14 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Meikle Phillip Terry Ii

      4 - Bone Biologics Corp (0001419554) (Issuer)

      10/18/24 8:27:04 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 3 filed by new insider Meikle Phillip Terry Ii

      3 - Bone Biologics Corp (0001419554) (Issuer)

      10/18/24 8:25:32 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Stroever Bruce

      4 - Bone Biologics Corp (0001419554) (Issuer)

      9/19/24 9:33:09 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Gagnon Robert E.

      4 - Bone Biologics Corp (0001419554) (Issuer)

      9/19/24 9:31:32 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Angle Siddhesh Rajendra

      4 - Bone Biologics Corp (0001419554) (Issuer)

      9/19/24 9:29:45 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Walsh Deina H

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/19/24 5:24:01 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Frelick Jeff

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/19/24 5:22:54 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Gagnon Robert E.

      4 - Bone Biologics Corp (0001419554) (Issuer)

      1/10/24 5:17:09 PM ET
      $BBLG
      Industrial Specialties
      Health Care

    Bone Biologics Corp Leadership Updates

    Live Leadership Updates

    See more

    Bone Biologics Corp Press Releases

    Fastest customizable press release news feed in the world

    See more

    Bone Biologics Corp SEC Filings

    See more
    • Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

      Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

      10/21/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

      Brings 20+ years of experience in finance and business operations at both public and private life sciences companies Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RN

      1/11/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

      Brings 30+ years of commercial experience in the orthopedic and spine industry Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company's board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four. Mr. Meikle most recently was president and chief executive officer of Biosystems of New England, Inc., an orthopedic distribution company that he founded in 1992 and sold to Stryker Corporation in 2019. He

      10/21/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics' company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern time. The presentation will be available on the company's website for a period of time here. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can regis

      9/4/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276771). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for t

      8/2/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

      Reminder: Management "CEO Chat" with Zacks Small-Cap Research Analyst Begins Today at 11 a.m. Eastern Time Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company's NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration. This pilot clinical study will evaluate NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degene

      6/20/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Executives to be Interviewed in a "CEO Chat" by Zacks Small-Cap Research Analyst on June 20th

      BURLINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, the Company's president and chief executive officer, and Deina Walsh, chief financial officer, will be interviewed by Zacks Small-Cap Research analyst Brad Sorensen, CFA in a "CEO Chat" on June 20th at the Life Science Investor Forum with Virtual Investor Conference hosted by VirtualInvestorConferences.com. The interview will begin at 11:00 a.m. Eastern time and can be viewed here. Investors are encouraged to preregister to expedite participation an

      6/17/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Announces Closing of $2.0 Million Public Offering

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants have an exercise price of $2.43 per share, are exercisable immediately upon issuance and will expire five years after the date of issuance. H.C. Wainwright & Co. acted as the exclus

      3/6/24 4:15:00 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Announces Pricing of $2.0 Million Public Offering

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $2.43 per share, will be exercisable immediately upon issuance and will expire five years after the date of issuance. The closing of the offering is expected to occur on or

      3/4/24 9:15:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Reports Progress With NB1 Clinical Program

      Bone Biologics Corporation (NASDAQ:BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion. Following Human Research Ethics Committee (HREC) approval last year in Australia for the multicenter, prospective, randomized pilot clinical trial, the Company reports that three hospital sites have been engaged to participate in the pilot clinical trial. This pilot clinical trial will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD). Inclusion criteria include patien

      3/1/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

      Brings 20+ years of experience in finance and business operations at both public and private life sciences companies Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company's board of directors. Mr. Gagnon fills the seat left by Erick Lucera, who has resigned effective upon Mr. Gagnon's appointment. The number of directors of Bone Biologics remains at four. Mr. Gagnon is currently chief financial officer of Remix Therapeutics, a clinical stage company focused on small molecule-mediated reprogramming of RN

      1/11/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

      Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on The Nasdaq Capital Market, but will remain under Nasdaq's discretionary panel monitor until June 28, 2024. Bone Biologics was notified by Nasdaq on Septe

      1/10/24 8:00:00 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form DEF 14A filed by Bone Biologics Corp

      DEF 14A - Bone Biologics Corp (0001419554) (Filer)

      4/23/25 8:00:36 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form PRE 14A filed by Bone Biologics Corp

      PRE 14A - Bone Biologics Corp (0001419554) (Filer)

      4/11/25 5:05:39 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by Bone Biologics Corp

      8-K - Bone Biologics Corp (0001419554) (Filer)

      4/1/25 5:15:18 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 10-K filed by Bone Biologics Corp

      10-K - Bone Biologics Corp (0001419554) (Filer)

      2/26/25 5:00:26 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bone Biologics Corp (0001419554) (Filer)

      12/13/24 5:05:20 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 424B5 filed by Bone Biologics Corp

      424B5 - Bone Biologics Corp (0001419554) (Filer)

      12/13/24 5:00:46 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Bone Biologics Corp

      10-Q - Bone Biologics Corp (0001419554) (Filer)

      11/14/24 5:00:51 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Corp filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Bone Biologics Corp (0001419554) (Filer)

      10/21/24 8:05:21 AM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Corp filed SEC Form 8-K: Leadership Update

      8-K - Bone Biologics Corp (0001419554) (Filer)

      10/4/24 5:00:41 PM ET
      $BBLG
      Industrial Specialties
      Health Care
    • Bone Biologics Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Bone Biologics Corp (0001419554) (Filer)

      9/27/24 5:05:28 PM ET
      $BBLG
      Industrial Specialties
      Health Care